Ford Motor Company vs NeoGenomics Inc. Common Stock — how do they compare? Ford Motor Company trades at $12.07 (market cap $48.25B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.14B). The key difference: Ford Motor Company is far larger — about 22.5× NeoGenomics Inc. Common Stock's market cap, and Ford Motor Company pays a 4.96% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| F | NEO | |
|---|---|---|
Market Cap | $48.25B | $2.14B |
Volume | 33,627,673 | 2,228,400 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $19.91 |
52-Week Low | $11.21 | $7.19 |
Typical Hold Time | 105 Days | 0 Days |
Enterprise Value | $180.21B | $2.44B |
Dividend Yield | 4.96% | — |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.10, up 0.83% with bearish technical indicators. The company reported mixed Q2 2026 earnings, beating expectations but showing negative profitability metrics including -3.93% net income margin. Recent news highlights sales declines and production challenges, though the company maintains strong cash flow from operations of $21.28 billion in 2025.
Ford faces headwinds from declining sales and profitability challenges, offset by strong commercial division performance and positive analyst sentiment with a $15.79 price target. Key risks include competitive pressure from Asian automakers and ongoing production disruptions, while the current valuation appears attractive with P/E of 11.21 and P/S of 0.26.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →